The company currently holds zero balance in liabilities with Debt to Equity (D/E) ratio of 2.6 implying the stock greatly relies on financing operations through barrowing. ABIOMED has Current Ratio of 6.26 suggesting that it is liquid enough and is able to pay its financial obligations when they are due. This firm dividends can provide a clue to current valuation of the stock. ABIOMED is not expected to issue dividends this year as it trying to preserve or re-invest any of the funds available for distribution to stakeholders. The company has Profit Margin (PM) of 33.66 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 29.22 % which suggests for every 100 dollars of sales it generated a net operating income of 0.29.
ABIOMED
financial leverage refers to using borrowed capital as a funding source to finance ABIOMED ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. ABIOMED financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to ABIOMED's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of ABIOMED's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between ABIOMED's total debt and its cash.
To perform a cash flow analysis of ABIOMED, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash ABIOMED is receiving and how much cash it distributes out in a given period. The ABIOMED cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
The entity has beta of 1.13. ABIOMED returns are very sensitive to returns on the market. As market goes up or down, ABIOMED is expected to follow. The small decline in market price for the last few months could raise concerns from investors as the entity closed today at a share price of
262.83 on
695368.000 in volume. The company executives did not add much value to ABIOMED investors in
April. However, diversifying your holdings with ABIOMED or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 1.9693. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. ABIOMED discloses 769.43m in revenue. ABIOMED is trading at 270.39. This is 2.95 percent increase. Day Low was 262.83. ABIOMED Net Cash Flow Investment Acquisitions and Disposals is decreasing over the last 5 years. The previous year value of ABIOMED Net Cash Flow Investment Acquisitions and Disposals was 30,037,218. Further, ABIOMED Revenues USD is rather stable at the moment.
| Revenues USD | Revenues |
| 2013 | 0.00 | 0.00 |
| 2014 | 0.00 | 0.00 |
| 2015 | 0.00 | 0.00 |
| 2018 | 0.00 | 0.00 |
| 2019 (projected) | 0.00 | 0.00 |
To sum up, our research shows that ABIOMED is very steady with
below average odds of financial turmoil in the next two years. Our present buy or sell advice on the firm is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectVlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of ABIOMED. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com